Manuel Mohr
Co-Founder & Chief Executive Officer D2B3, Inc.
Scientist and biotech entrepreneur with experience in company formation, opportunity assessment, and scientific and corporate strategy in early-stage ventures. Proven track record in leveraging scientific innovations for commercial success, particularly in cell and gene therapies (CRISPR, CAR-T), with core expertise spanning viral/non-viral delivery systems, neurobiology, therapeutics and platforms, and biotech market strategy. Fluent in German and English, with foundational skills in French and Spanish, and over 12 years of experience driving cross-functional collaboration in multicultural environments.
Seminars
Understanding what drives successful partnerships is critical for emerging oligonucleotide companies looking to secure investment, collaboration or acquisition opportunities. This candid panel will bring together pharma business development, external innovation and investment leaders to discuss what truly differentiates programs that attract strategic interest, from scientific validation and platform maturity to team capabilities and commercial potential.
- Hear directly from pharma BD and external innovation leaders on the scientific, technical and strategic signals that make an oligonucleotide programme stand out as a partnership opportunity
- Gain insight into how companies should position emerging platforms, technologies and assets to align with evolving pharma priorities and investment strategies
- Ask your questions directly and understand what decision-makers are evaluating when considering partnerships, collaborations and future opportunities
